Bracco Gains Canadian Approval for Lower-Dose MRI Contrast Agent
Event summary
- Bracco Imaging received Health Canada approval for VUEWAY® injection (gadopiclenol), a macrocyclic gadolinium-based contrast agent.
- VUEWAY® requires a dose of 0.05 mmol/kg, half the standard dose of other GBCAs, reducing patient gadolinium exposure.
- The approval follows prior approvals in the United States (2022) and the European Union (2023), bringing the total approved countries to 37.
- Over 4 million patient doses of VUEWAY® have been administered globally.
The big picture
The approval of VUEWAY® reflects a growing emphasis on minimizing patient exposure to gadolinium and reducing the environmental impact of contrast agents. This trend is driven by increasing regulatory scrutiny and evolving clinical guidelines. Bracco’s collaboration with Guerbet, while accelerating development, also introduces a shared-ownership dynamic that could impact long-term profitability and strategic flexibility.
What we're watching
- Market Adoption
- The speed of VUEWAY’s adoption in Canada will depend on physician acceptance and reimbursement rates, potentially impacting Bracco’s overall revenue growth in the region.
- Competitive Response
- Other contrast agent manufacturers will likely respond to VUEWAY’s lower-dose approach, potentially leading to price pressure or the development of competing products with similar benefits.
- IP Landscape
- The ongoing collaboration and IP ownership structure between Bracco and Guerbet could create complexities and influence future commercialization strategies for gadopiclenol.
Related topics